Related Experiment Video
Updated: Jun 17, 2026
08:18
A Small-Scale Setup for Algal Toxicity Testing of Nanomaterials and Other Difficult Substances
Published on: October 10, 2020
Nanomaterial standards for efficacy and toxicity assessment
Pavan P Adiseshaiah1, Jennifer B Hall, Scott E McNeil
1Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, National Cancer Institute at Frederick, Frederick, MD 21702, USA. adiseshaiahp@mail.nih.gov
Summary
Nanotechnology enables targeted cancer drug delivery, reducing toxicity. Optimizing nanomedicine design based on its properties and tumor characteristics is key for effective cancer treatment.
Area of Science:
- Nanomedicine
- Cancer Therapeutics
- Biotechnology
Background:
- Nanotechnology has significantly advanced targeted cancer drug delivery, aiming to reduce systemic toxicity.
- Effective nanomedicine requires reaching cancer cells in sufficient quantities and activating within the tumor microenvironment.
- Tumor accumulation is often achieved through the enhanced permeability and retention (EPR) effect, sometimes combined with active targeting.
Purpose of the Study:
- To review how physicochemical properties of nanomedicines influence their tumor distribution, vascular transport, and retention.
- To discuss nanoparticle characteristics affecting efficacy post-accumulation, including stability, drug release, cellular uptake, and cytotoxicity.
- To elaborate on how tumor-specific variations impact nanomedicine response and to guide the design of in vivo efficacy studies.
Main Methods:
- Literature review of nanomedicine properties and their impact on pharmacokinetics and pharmacodynamics.
- Analysis of factors influencing nanomedicine accumulation and activity within the tumor microenvironment.
- Synthesis of knowledge to inform the design of in vivo evaluation studies for nanomedicines.
Main Results:
- Physicochemical properties (size, charge, hydrophobicity) critically affect nanomedicine biodistribution, tumor penetration, and retention.
- Nanoparticle stability, drug release kinetics, cellular uptake efficiency, and cytotoxicity are crucial for therapeutic outcomes.
- Tumor heterogeneity (vascularization, receptor expression) varies significantly, influencing nanomedicine efficacy across different cancer types and stages.
Conclusions:
- Understanding the interplay between nanomedicine properties and tumor characteristics is essential for designing effective targeted cancer therapies.
- Tailoring nanomedicine design and in vivo testing strategies to specific tumor microenvironments can optimize therapeutic outcomes.
- This knowledge facilitates the development of more efficacious and less toxic cancer treatments through nanotechnology.
